• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Juventas wins approval for a Phase 2 trial on critical limb ischemia treatment

Juventas wins approval for a Phase 2 trial on critical limb ischemia treatment

January 4, 2011 By MedCity News

Juventas logo

Juventas hopes to begin enrolling patients in a trial of its regenerative medicine technology beginning in the second quarter, and complete enrollment by the end of the year, CEO Rahul Aras said.

Critical limb ischemia is a severe obstruction of the arteries that decreases blood flow to the extremities and can result in amputation.

Juventas is able to forego a Phase 1 trial for CLI patients because it’ll leverage its clinical data from a Phase 1 trial of heart failure patients. The heart failure clinical trial began enrollment in April.

Juventas’ technology, called JVS-100, is based on a growth factor that in adults recruits stem cells from the bone marrow to create new blood vessels. The factor acts as a “beacon,” recruiting stem cells to repair a damaged organ, Aras said.

MedCity News logo

The company’s technology was pioneered by Dr. Marc Penn, medical director of the Cleveland Clinic’s cardiac intensive care unit. Penn is Juventas’ chief medical officer. Aras was previously an executive with Cleveland Clinic Innovations, the health system’s technology transfer unit.

Aside from the trial, much of Juventas’ focus in 2011 will be on fundraising. The company will need between $25 million and $30 million to fund the CLI and heart-failure trials, Aras said.

So far, four-employee Juventas has raised about $10 million through angel funding, venture capital and grants since its 2007 inception, Aras said. Investors include Triathlon Medical Ventures and Blue Chip Venture Co., both in Cincinnati, plus JumpStart Inc. and North Coast Angel Fund.

Aras projected 2015 or 2016 for when Juventas would get its first product on the market. It’s not yet clear whether the company will look to first market JVS-100 to CLI or heart failure patients, he said.

Filed Under: Business/Financial News, News Well, Regenerative Medicine Tagged With: Juventas Therapeutics Inc.

More recent news

  • Zynex submits laser pulse oximeter to FDA
  • Roche invests $550M to make Indianapolis a CGM manufacturing hub
  • Product liability lawsuits target Medtronic, Boston Scientific spinal cord stim tech
  • GE HealthCare launches new MRI scanner
  • HistoSonics earns first major reimbursement win for non-invasive histotripsy

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy